Squarepoint’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $115K | Sell |
32,746
-56,134
| -63% | -$230K | ﹤0.01% | 4042 |
|
|
2025
Q4 | $300K | Buy |
88,880
+68,613
| +339% | +$178K | ﹤0.01% | 3608 |
|
|
2025
Q3 | $26.6K | Sell |
20,267
-59,600
| -75% | -$61.7K | ﹤0.01% | 4273 |
|
|
2025
Q2 | $57.3K | Buy |
+79,867
| New | +$62.7K | ﹤0.01% | 4286 |
|
|
2024
Q3 | – | Sell |
-105,566
| Closed | -$688K | – | 4383 |
|
|
2024
Q2 | $688K | Sell |
105,566
-179,194
| -63% | -$1.27M | ﹤0.01% | 2836 |
|
|
2024
Q1 | $2.48M | Buy |
284,760
+197,387
| +226% | +$2.4M | ﹤0.01% | 1951 |
|
|
2023
Q4 | $1,000K | Sell |
87,373
-422,834
| -83% | -$4.18M | ﹤0.01% | 2522 |
|
|
2023
Q3 | $4.91M | Buy |
510,207
+379,284
| +290% | +$3.72M | 0.01% | 1196 |
|
|
2023
Q2 | $1.39M | Sell |
130,923
-21,936
| -14% | -$236K | ﹤0.01% | 1921 |
|
|
2023
Q1 | $1.61M | Buy |
+152,859
| New | +$1.71M | 0.01% | 1565 |
|
|
2022
Q4 | – | Sell |
-133,494
| Closed | -$1.38M | – | 3396 |
|
|
2022
Q3 | $1.38M | Buy |
+133,494
| New | +$1.51M | 0.01% | 1552 |
|
|
2022
Q2 | – | Sell |
-85,687
| Closed | -$1.08M | – | 3116 |
|
|
2022
Q1 | $1.08M | Sell |
85,687
-86,700
| -50% | -$994K | ﹤0.01% | 1545 |
|
|
2021
Q4 | $2.01M | Sell |
172,387
-253,143
| -59% | -$3.11M | 0.01% | 1259 |
|
|
2021
Q3 | $5.56M | Buy |
425,530
+293,762
| +223% | +$3.8M | 0.02% | 723 |
|
|
2021
Q2 | $1.7M | Sell |
131,768
-60,824
| -32% | -$696K | 0.01% | 1293 |
|
|
2021
Q1 | $2.15M | Buy |
+192,592
| New | +$2.03M | 0.01% | 1025 |
|
|
2020
Q4 | – | Sell |
-28,753
| Closed | -$259K | – | 3086 |
|
|
2020
Q3 | $259K | Sell |
28,753
-99,694
| -78% | -$991K | ﹤0.01% | 1927 |
|
|
2020
Q2 | $1.33M | Sell |
128,447
-45,536
| -26% | -$466K | 0.02% | 797 |
|
|
2020
Q1 | $1.75M | Buy |
173,983
+157,689
| +968% | +$1.85M | 0.04% | 491 |
|
|
2019
Q4 | $217K | Sell |
16,294
-380,445
| -96% | -$4.19M | ﹤0.01% | 2194 |
|
|
2019
Q3 | $3.41M | Buy |
+396,739
| New | +$3.86M | 0.03% | 612 |
|
|
2019
Q2 | – | Sell |
-225,323
| Closed | -$2.55M | – | 2520 |
|
|
2019
Q1 | $2.55M | Buy |
225,323
+130,850
| +139% | +$1.46M | 0.03% | 672 |
|
|
2018
Q4 | $820K | Buy |
94,473
+54,952
| +139% | +$631K | 0.01% | 1004 |
|
|
2018
Q3 | $611K | Buy |
+39,521
| New | +$625K | 0.01% | 1218 |
|
|
2018
Q1 | – | Sell |
-21,451
| Closed | -$269K | – | 1913 |
|
|
2017
Q4 | $269K | Buy |
+21,451
| New | +$280K | ﹤0.01% | 1591 |
|
|
2017
Q2 | – | Sell |
-15,459
| Closed | -$221K | – | 1661 |
|
|
2017
Q1 | $221K | Sell |
15,459
-78,184
| -83% | -$1.07M | 0.01% | 1242 |
|
|
2016
Q4 | $1.2M | Buy |
93,643
+79,673
| +570% | +$1.01M | 0.05% | 437 |
|
|
2016
Q3 | $186K | Buy |
+13,970
| New | +$163K | 0.01% | 905 |
|
|
2016
Q2 | – | Sell |
-25,074
| Closed | -$230K | – | 1222 |
|
|
2016
Q1 | $230K | Sell |
25,074
-33,910
| -57% | -$280K | 0.02% | 941 |
|
|
2015
Q4 | $573K | Buy |
+58,984
| New | +$570K | 0.06% | 466 |
|
Other funds holding IRWD
AC
SCM
VPM
VCM
Squarepoint's IRWD Position: Q1 2026 in Review
Squarepoint reduced its Ironwood Pharmaceuticals (IRWD) stake by 63% in Q1 2026, selling an estimated $230K and leaving 32,746 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #4042.
Squarepoint first reported a position in IRWD in Q4 2015 and has held it in 30 quarters since. The position peaked at $5.56M in Q3 2021. 226 funds tracked by Wall St. Rank hold IRWD as of Q1 2026.
- Squarepoint held 32,746 shares of Ironwood Pharmaceuticals worth $115K as of Q1 2026.
- Squarepoint sold 56,134 Ironwood Pharmaceuticals shares in Q1 2026, an estimated $230K.
- Ironwood Pharmaceuticals made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4042 holding.
- Squarepoint first reported a position in Ironwood Pharmaceuticals in Q4 2015 and has held it in 30 quarters since.
- Squarepoint's Ironwood Pharmaceuticals position peaked at $5.56M in Q3 2021.
- 226 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.